Laboratory Medicine ›› 2017, Vol. 32 ›› Issue (4): 316-321.DOI: 10.3969/j.issn.1673-8640.2017.04.016
• Orginal Article • Previous Articles Next Articles
SONG Rui1, YE Ping1, WEI Chaohui2, CHEN Xiaoxiang1, WANG Jiucun3
Received:
2016-08-29
Online:
2017-04-20
Published:
2017-05-01
CLC Number:
SONG Rui, YE Ping, WEI Chaohui, CHEN Xiaoxiang, WANG Jiucun. Correlation of systemic lupus erythematosus clinical phenotypes with anti-double-stranded DNA antibodies and performance comparison of 4 commercial determination kits[J]. Laboratory Medicine, 2017, 32(4): 316-321.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2017.04.016
组别 | 例数 | 抗核小体抗体 | 抗核抗体 | 狼疮肾炎 | |||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | ||||||||||||||||||||||||||||||||
SLE组 | 229 | 114(49.8) | 115(50.2) | 214(93.4) | 5(6.6) | 92(40.2) | 137(59.8) | ||||||||||||||||||||||||||||||
其他结缔组织病组 | 112 | 4(3.6) | 108(96.4) | 51(45.5) | 61(54.5) | 3(2.7) | 109(97.3) | ||||||||||||||||||||||||||||||
χ2值 | 68.95 | 99.70 | 50.77 | ||||||||||||||||||||||||||||||||||
P值 | <0.01 | <0.01 | <0.01 | ||||||||||||||||||||||||||||||||||
组别 | 例数 | 补体低 | 白细胞减少 | 血小板减少 | |||||||||||||||||||||||||||||||||
阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | ||||||||||||||||||||||||||||||||
SLE组 | 229 | 130(56.8) | 99(43.2) | 35(15.3) | 194(84.7) | 31(13.5) | 198(86.5) | ||||||||||||||||||||||||||||||
其他结缔组织病组 | 112 | 7(6.3) | 105(93.7) | 7(6.3) | 105(93.7) | 7(6.3) | 105(93.7) | ||||||||||||||||||||||||||||||
χ2值 | 79.87 | 5.68 | 4.03 | ||||||||||||||||||||||||||||||||||
P值 | <0.01 | 0.02 | 0.04 | ||||||||||||||||||||||||||||||||||
组别 | 例数 | 外周关节炎 | 颊部红斑 | 口鼻黏膜溃疡 | |||||||||||||||||||||||||||||||||
阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | ||||||||||||||||||||||||||||||||
SLE组 | 229 | 54(23.6) | 175(76.4) | 76(33.2) | 153(66.8) | 19(8.3) | 210(91.7) | ||||||||||||||||||||||||||||||
其他结缔组织病组 | 112 | 54(48.2) | 58(51.8) | 40(35.7) | 72(64.3) | 10(8.9) | 102(91.1) | ||||||||||||||||||||||||||||||
χ2值 | 21.09 | 0.21 | 0.04 | ||||||||||||||||||||||||||||||||||
P值 | <0.01 | 0.64 | 0.84 | ||||||||||||||||||||||||||||||||||
组别 | 例数 | 脱发 | 盘状红斑 | 胸膜炎 | |||||||||||||||||||||||||||||||||
阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | ||||||||||||||||||||||||||||||||
SLE组 | 229 | 27(11.8) | 202(88.2) | 0(0.0) | 229(100.0) | 12(5.2) | 217(94.8) | ||||||||||||||||||||||||||||||
其他结缔组织病组 | 112 | 3(2.7) | 109(97.3) | 0(0.0) | 112(100.0) | 0(0.0) | 112(100.0) | ||||||||||||||||||||||||||||||
χ2值 | 6.69 | 4.64 | |||||||||||||||||||||||||||||||||||
P值 | 0.01 | 0.03 | |||||||||||||||||||||||||||||||||||
组别 | 例数 | 狼疮脑病 | 发热 | 胸膜炎 | |||||||||||||||||||||||||||||||||
阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | ||||||||||||||||||||||||||||||||
SLE组 | 229 | 6(2.6) | 223(97.4) | 32(14.0) | 197(86.0) | 3(1.3) | 226(98.7) | ||||||||||||||||||||||||||||||
其他结缔组织病组 | 112 | 0(0.0) | 112(100.0) | 16(14.3) | 96(85.7) | 0(0.0) | 112(100.0) | ||||||||||||||||||||||||||||||
χ2值 | 1.66 | 0.01 | 0.36 | ||||||||||||||||||||||||||||||||||
P值 | 0.20 | 0.94 | 0.55 |
组别 | 例数 | 抗核小体抗体 | 抗核抗体 | 狼疮肾炎 | |||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | ||||||||||||||||||||||||||||||||
SLE组 | 229 | 114(49.8) | 115(50.2) | 214(93.4) | 5(6.6) | 92(40.2) | 137(59.8) | ||||||||||||||||||||||||||||||
其他结缔组织病组 | 112 | 4(3.6) | 108(96.4) | 51(45.5) | 61(54.5) | 3(2.7) | 109(97.3) | ||||||||||||||||||||||||||||||
χ2值 | 68.95 | 99.70 | 50.77 | ||||||||||||||||||||||||||||||||||
P值 | <0.01 | <0.01 | <0.01 | ||||||||||||||||||||||||||||||||||
组别 | 例数 | 补体低 | 白细胞减少 | 血小板减少 | |||||||||||||||||||||||||||||||||
阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | ||||||||||||||||||||||||||||||||
SLE组 | 229 | 130(56.8) | 99(43.2) | 35(15.3) | 194(84.7) | 31(13.5) | 198(86.5) | ||||||||||||||||||||||||||||||
其他结缔组织病组 | 112 | 7(6.3) | 105(93.7) | 7(6.3) | 105(93.7) | 7(6.3) | 105(93.7) | ||||||||||||||||||||||||||||||
χ2值 | 79.87 | 5.68 | 4.03 | ||||||||||||||||||||||||||||||||||
P值 | <0.01 | 0.02 | 0.04 | ||||||||||||||||||||||||||||||||||
组别 | 例数 | 外周关节炎 | 颊部红斑 | 口鼻黏膜溃疡 | |||||||||||||||||||||||||||||||||
阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | ||||||||||||||||||||||||||||||||
SLE组 | 229 | 54(23.6) | 175(76.4) | 76(33.2) | 153(66.8) | 19(8.3) | 210(91.7) | ||||||||||||||||||||||||||||||
其他结缔组织病组 | 112 | 54(48.2) | 58(51.8) | 40(35.7) | 72(64.3) | 10(8.9) | 102(91.1) | ||||||||||||||||||||||||||||||
χ2值 | 21.09 | 0.21 | 0.04 | ||||||||||||||||||||||||||||||||||
P值 | <0.01 | 0.64 | 0.84 | ||||||||||||||||||||||||||||||||||
组别 | 例数 | 脱发 | 盘状红斑 | 胸膜炎 | |||||||||||||||||||||||||||||||||
阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | ||||||||||||||||||||||||||||||||
SLE组 | 229 | 27(11.8) | 202(88.2) | 0(0.0) | 229(100.0) | 12(5.2) | 217(94.8) | ||||||||||||||||||||||||||||||
其他结缔组织病组 | 112 | 3(2.7) | 109(97.3) | 0(0.0) | 112(100.0) | 0(0.0) | 112(100.0) | ||||||||||||||||||||||||||||||
χ2值 | 6.69 | 4.64 | |||||||||||||||||||||||||||||||||||
P值 | 0.01 | 0.03 | |||||||||||||||||||||||||||||||||||
组别 | 例数 | 狼疮脑病 | 发热 | 胸膜炎 | |||||||||||||||||||||||||||||||||
阳性 | 阴性 | 阳性 | 阴性 | 阳性 | 阴性 | ||||||||||||||||||||||||||||||||
SLE组 | 229 | 6(2.6) | 223(97.4) | 32(14.0) | 197(86.0) | 3(1.3) | 226(98.7) | ||||||||||||||||||||||||||||||
其他结缔组织病组 | 112 | 0(0.0) | 112(100.0) | 16(14.3) | 96(85.7) | 0(0.0) | 112(100.0) | ||||||||||||||||||||||||||||||
χ2值 | 1.66 | 0.01 | 0.36 | ||||||||||||||||||||||||||||||||||
P值 | 0.20 | 0.94 | 0.55 |
试剂盒 | 方法 | 抗原 | 参考值 |
---|---|---|---|
A | IFA | 绿蝇短膜虫动基体 | <1∶10 |
B | ELISA | 结合核小体dsDNA | <100 IU/mL |
C | ELISA | 免疫亲和吸附纯化的人dsDNA | <77 IU/mL |
D | 放射免疫法 | 重组质粒dsDNA | <10 IU/mL |
试剂盒 | 方法 | 抗原 | 参考值 |
---|---|---|---|
A | IFA | 绿蝇短膜虫动基体 | <1∶10 |
B | ELISA | 结合核小体dsDNA | <100 IU/mL |
C | ELISA | 免疫亲和吸附纯化的人dsDNA | <77 IU/mL |
D | 放射免疫法 | 重组质粒dsDNA | <10 IU/mL |
组别 | 例数 | 试剂盒A | 试剂盒B | 试剂盒C | 试剂盒D |
---|---|---|---|---|---|
SLE组 | 229 | 61(26.6) | 94(41.0) | 167(72.9) | 134(58.5) |
活动期组 | 131 | 53(40.5) | 72(55.0) | 114(87.0) | 112(85.5) |
非活动期组 | 98 | 8(8.2) | 22(22.4) | 53(54.1) | 22(22.4) |
其他结缔组织病组 | 112 | 0(0.0) | 2(1.8) | 2(1.8) | 4(3.6) |
组别 | 例数 | 试剂盒A | 试剂盒B | 试剂盒C | 试剂盒D |
---|---|---|---|---|---|
SLE组 | 229 | 61(26.6) | 94(41.0) | 167(72.9) | 134(58.5) |
活动期组 | 131 | 53(40.5) | 72(55.0) | 114(87.0) | 112(85.5) |
非活动期组 | 98 | 8(8.2) | 22(22.4) | 53(54.1) | 22(22.4) |
其他结缔组织病组 | 112 | 0(0.0) | 2(1.8) | 2(1.8) | 4(3.6) |
试剂盒 | 敏感性(%) | 特异性(%) | Youden指数 |
---|---|---|---|
A | 26.6 | 100.0 | 0.266 |
B | 41.0 | 98.2 | 0.392 |
C | 72.9 | 98.2 | 0.711 |
D | 58.5 | 96.4 | 0.549 |
试剂盒 | 敏感性(%) | 特异性(%) | Youden指数 |
---|---|---|---|
A | 26.6 | 100.0 | 0.266 |
B | 41.0 | 98.2 | 0.392 |
C | 72.9 | 98.2 | 0.711 |
D | 58.5 | 96.4 | 0.549 |
临床表型及指标 | OR值(95%可信区间) | |||
---|---|---|---|---|
试剂盒A | 试剂盒B | 试剂盒C | 试剂盒D | |
抗核小体抗体 | 6.26(2.59~15.15)** | 18.31(8.26~40.6)** | 9.2(4.06~20.85)** | 3.30(1.63~6.66)** |
抗核抗体 | 3.89(0.48~31.82) | 6.47(0.80~52.5) | 17.19(4.96~59.59)** | 5.17(1.43~18.65)* |
狼疮肾炎 | 3.08(1.36~6.95)** | 0.99(0.42~2.36) | 0.85(0.38~1.94) | 2.12(1.02~4.40)* |
补体低 | 4.65(1.72~12.56)** | 2.88(1.17~7.07)* | 4.46(2.05~9.72)** | 4.65(2.25~9.64)** |
白细胞减少 | 3.25(1.26~8.36)* | 1.69(0.62~4.62) | 1.47(0.49~4.39) | 2.72(1.05~7.07)* |
血小板减少 | 0.58(0.20~1.71) | 1.46(0.48~4.44) | 1.37(0.46~4.12) | 2.17(0.85~5.57) |
外周关节炎 | 1.63(0.74~3.61) | 0.56(0.23~1.35) | 0.48(0.22~1.05) | 1.15(0.55~2.41) |
颊部红斑 | 0.74(0.32~1.73) | 2.35(1.01~5.44)* | 1.33(0.57~3.07) | 2.22(1.06~4.65)* |
口鼻黏膜溃疡 | 0.18(0.04~0.77) | 2.87(0.59~13.88) | 4.95(0.53~46.02) | 0.43(0.12~1.60) |
脱发 | 1.11(0.35~3.52) | 1.32(0.382~4.56) | 1.81(0.38~8.59) | 1.48(0.46~4.76) |
胸膜炎 | 1.35(0.37~4.93) | 1.32(0.31~5.69) | NA | 7.24(0.71~73.63) |
狼疮脑病 | 0.44(0.04~5.12) | 1.26(0.17~9.47) | NA | 5.25(0.50~55.75) |
发热 | 0.78(0.29~2.08) | 1.15(0.43~3.05) | 0.48(0.17~1.33) | 0.68(0.27~1.73) |
血管炎 | 1.03(0.07~15.75) | NA | NA | 1.51(0.08~30.06) |
临床表型及指标 | OR值(95%可信区间) | |||
---|---|---|---|---|
试剂盒A | 试剂盒B | 试剂盒C | 试剂盒D | |
抗核小体抗体 | 6.26(2.59~15.15)** | 18.31(8.26~40.6)** | 9.2(4.06~20.85)** | 3.30(1.63~6.66)** |
抗核抗体 | 3.89(0.48~31.82) | 6.47(0.80~52.5) | 17.19(4.96~59.59)** | 5.17(1.43~18.65)* |
狼疮肾炎 | 3.08(1.36~6.95)** | 0.99(0.42~2.36) | 0.85(0.38~1.94) | 2.12(1.02~4.40)* |
补体低 | 4.65(1.72~12.56)** | 2.88(1.17~7.07)* | 4.46(2.05~9.72)** | 4.65(2.25~9.64)** |
白细胞减少 | 3.25(1.26~8.36)* | 1.69(0.62~4.62) | 1.47(0.49~4.39) | 2.72(1.05~7.07)* |
血小板减少 | 0.58(0.20~1.71) | 1.46(0.48~4.44) | 1.37(0.46~4.12) | 2.17(0.85~5.57) |
外周关节炎 | 1.63(0.74~3.61) | 0.56(0.23~1.35) | 0.48(0.22~1.05) | 1.15(0.55~2.41) |
颊部红斑 | 0.74(0.32~1.73) | 2.35(1.01~5.44)* | 1.33(0.57~3.07) | 2.22(1.06~4.65)* |
口鼻黏膜溃疡 | 0.18(0.04~0.77) | 2.87(0.59~13.88) | 4.95(0.53~46.02) | 0.43(0.12~1.60) |
脱发 | 1.11(0.35~3.52) | 1.32(0.382~4.56) | 1.81(0.38~8.59) | 1.48(0.46~4.76) |
胸膜炎 | 1.35(0.37~4.93) | 1.32(0.31~5.69) | NA | 7.24(0.71~73.63) |
狼疮脑病 | 0.44(0.04~5.12) | 1.26(0.17~9.47) | NA | 5.25(0.50~55.75) |
发热 | 0.78(0.29~2.08) | 1.15(0.43~3.05) | 0.48(0.17~1.33) | 0.68(0.27~1.73) |
血管炎 | 1.03(0.07~15.75) | NA | NA | 1.51(0.08~30.06) |
[1] | ZEN M,BASSI N,NALOTTO L,et al.Disease activity patterns in a monocentric cohort of SLE patients:a seven-year follow-up study[J]. Clin Exp Rheumatol,2012,30(6):856-863. |
[2] | GATTO M,ZEN M,GHIRARDELLO A,et al.Emerging and critical issues in the pathogenesis of lupus[J]. Autoimmun Rev,2013,12(4):523-536. |
[3] | DORIA A,ZEN M,CANOVA M,et al.SLE diagnosis and treatment:when early is early[J]. Autoimmune Rev,2010,10:55-60. |
[4] | LINNIK M D,HU J Z,HEILBRUNN K R,et al.Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2005,52(4):1129-1137. |
[5] | FOSTER M H.T cells and B cells in lupus nephritis[J]. Semin Nephrol,2007,27(1):47-58. |
[6] | PETRI M,ORBAI A M,ALARCON G S,et al.Derivation and validation of the Systemic Lupus In-ternational Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum,2012,64(8):2677-2686. |
[7] | FENTON K,FISMEN S,HEDBERG A,et al.Anti-dsDNA antibodies promote initiation,and acquired loss of renal Dnase 1 promotes progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice[J]. PLoS One,2009,4(12):e8474. |
[8] | FISMEN S,HEDBERG A,FENTON K A,et al.Circulating chromatin-antichromatin antibody complexes bind with high affinity to dermo-epidermal structures in murine and human lupus nephritis[J]. Lupus,2009,18(7):597-607. |
[9] | GROOTSCHOLTEN C,VAN BRUGGEN M C,VAN DER PIJL J W,et al. Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus ne-phritis[J]. Arthritis Rheum,2003,48:1355-1362. |
[10] | HUERTA P T,KOWAL C,DEGIORGIO L A,et al.Immunity and behavior:antibodies alter emotion[J]. Proc Natl Acad Sci U S A,2006,103(3):678-683. |
[11] | HAUGBRO K,NOSSENT J C,WINKLER T,et al.Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients:the role of analytical diversity[J]. Ann Rheum Dis,2004,63(4):386-394. |
[12] | JANG Y J,STOLLAR B D.Anti-DNA antibodies:aspects of structure and pathogenicity[J]. Cell Mol Life Sci,2003,60(2):309-320. |
[13] | KALSI J K,MARTIN A C,HIRABAYASHI Y,et al.Functional and modeling studies of the binding of human monoclonal anti-DNA antibodies to DNA[J]. Mol Immunol,1996,33(4-5):471-483. |
[14] | STOLLAR B D.Immunochemistry of DNA[J]. Int Rev Immunol,1989,5(1):1-22. |
[15] | BERDEN J H.Lupus nephritis:consequence of disturbed removal of apoptotic cells?[J]. Neth J Med,2003,61(8):233-238. |
[16] | FISMEN S,MORTENSEN E S,REKVIG O P.Nuclease deficiencies promote end-stage lupus nephritis but not nephritogenic autoimmunity in (NZB×NZW) F1 mice[J]. Immunol Cell Biol,2011,89(1):90-99. |
[17] | KRUSE K,JANKO C,URBONAVICIUTE V,et al.Inefficient clearance of dying cells in patients with SLE:anti-dsDNA autoantibodies,MFG-E8,HMGB-1 and other players[J]. Apoptosis,2010,15(9):1098-1113. |
[18] | MUÑOZ L E,JANKO C,SCHULZE C,et al. Autoimmunity and chronic inflammation-two clear-ance-related steps in the etiopathogenesis of SLE[J]. Autoimmun Rev,2010,10(1):38-42. |
[19] | URBONAVICIUTE V,FüRNROHR B G,MEISTER S,et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes:implications for the pathogenesis of SLE[J]. J Exp Med,2008,205(13):3007-3018. |
[20] | REKVIG O P.Anti-dsDNA antibodies as a classification criterion and a diagnostic marker for sys-temic lupus erythematosus:critical remarks[J]. Clin Exp Immunol,2015,179(1):5-10. |
[21] | AMITAL H,HEILWEIL M,ULMANSKY R,et al.Treatment with a laminin-derived peptide suppresses lupus nephritis[J]. J Immunol,2005,175(8):5516-5523. |
[22] | KALAAJI M,MORTENSEN E,JRGENSEN L,et al.Nephritogenic lupus antibodies recognize glo-merular basement membrane-associated chromatin fragments released from apoptotic in-traglomerular cells[J]. Am J Pathol,2006,168(6):1779-1792. |
[23] | MJELLE J E,REKVIG O P,FENTON K A.Nucleosomes possess a high affinity for glomerular laminin and collagen Ⅳ and bind nephritogenic antibodies in murine lupus-like nephritis[J]. Ann Rheum Dis,2007,66(12):1661-1668. |
[24] | FUCHS T A,ABED U,GOOSMANN C,et al.Novel cell death program leads to neutrophil extracellular traps[J]. J Cell Biol,2007,176(2):231-241. |
[1] | LÜ Yingxia, YANG Junmei, ZHENG Lijuan, HUANG Qinghua. Expression of TLR-4 and HMGB1 in peripheral blood of children with SLE and its clinical significance [J]. Laboratory Medicine, 2020, 35(11): 1143-1146. |
[2] | CHEN Yanhong, SUN Li, FU Yu, LIU Yan, NIU Guoping. Clinical application of plasma GAS5 in the diagnosis and treatment of systemic lupus erythematosus [J]. Laboratory Medicine, 2019, 34(8): 696-700. |
[3] | WANG Xia, SUO Minghuan, HU Ting, HU Yaozong, WEN Dongmei. Expressions and roles of serum IL-33 and sST2 in children with systemic lupus erythematosus [J]. Laboratory Medicine, 2019, 34(6): 518-521. |
[4] | XU Liming, SHEN Jun. Role of serum adiponectin determination combined with leptin in the diagnosis of lupus nephritis [J]. Laboratory Medicine, 2019, 34(5): 401-404. |
[5] | TAN Liming, JIAO Anjun, FENG Xiaojing, XU Liuyue, TAN Fuyan, HE Siqi, LUO Heng, CHEN Juanjuan, JIANG Yongqing, LI Hua. Anti-neutrophil cytoplasmic antibody determination for systemic vasculitis [J]. Laboratory Medicine, 2018, 33(2): 101-105. |
[6] | SONG Rui, YE Ping, CHEN Xiaoxiang. Correlations between IgG,IgM and IgA anti-ds-DNA antibodies and systemic lupus erythematosus [J]. Laboratory Medicine, 2018, 33(11): 969-974. |
[7] | CHEN Shuimian, YU Chongzhao, LI Enling, ZHU Haoming, LU Jingbo, ZHENG Bing. Autoantibody-related parameters in patients with autoimmune diseases and healthy subjects [J]. Laboratory Medicine, 2018, 33(1): 31-36. |
[8] | TAN Liming, DING Yaodong, CHEN Juanjuan, LI Hua, JIANG Yongqing, WAN Yani, WANG Liyun, WANG Tian. Complement 1q determination for autoimmune diseases [J]. Laboratory Medicine, 2017, 32(8): 686-690. |
[9] | XU Weijia 1,LI Zhi 1,YANG Tingting 2 ,WANG Bo 1. The changes and clinical significance on the expressions of Th17, Th1 and cytokines in patients with systemic lupus erythematosus [J]. , 2013, 28(5): 396-399. |
[10] | WU Yehong;ZHAO Rongping;XU Yanping. The clinical significance of detecting urinary neutrophil gelatinase-associated lipocalin in SLE kidney disease [J]. , 2012, 27(3): 189-191. |
[11] | LIU Mengqiong;LIN Yongqian;WANG Qiaomei;GU Sheng. The significance of serum MMP-2 and MMP-9 levels and activities determination in patients with rheumatoid arthritis and systemic lupus erythematosus [J]. , 2009, 24(12): 883-885. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||